Clinical Study of the inQB8 TTVR System

NCT ID: NCT06611579

Last Updated: 2025-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-01

Study Completion Date

2029-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a multi-center, prospective, single-arm study to assess safety and performance of the inQB8 Medical Technologies MonarQ Tricuspid Valve Replacement System.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tricuspid Valve Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Treatment with the inQB8 MonarQ Transcatheter Tricuspid Valve Replacement System

Group Type EXPERIMENTAL

Transcatheter Tricuspid Valve Replacement

Intervention Type DEVICE

Replacement of the tricuspid valve using a transcatheter approach

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcatheter Tricuspid Valve Replacement

Replacement of the tricuspid valve using a transcatheter approach

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

inQB8 MonarQ Transcatheter Tricuspid Valve Replacement System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Anatomically suitable for the MonarQ TTVR System
* Symptomatic, tricuspid regurgitation (TR) that is severe or greater
* Adequately treated for heart failure based upon medical standards
* Hemodynamically stable

Exclusion Criteria

* Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days
* Refractory Heart Failure (HF) that requires or required advanced intervention
* Any condition, in the opinion of the investigator, making it unlikely the patient will be able to complete all protocol procedures and follow-up.
* Currently participating in another investigational biologic, drug or device study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

inQB8 Medical Technologies, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status RECRUITING

Los Robles Hosptial and Medical Center

Thousand Oaks, California, United States

Site Status RECRUITING

Piedmont Atlanta Hospital

Atlanta, Georgia, United States

Site Status RECRUITING

North Shore University Hospital

Manhasset, New York, United States

Site Status RECRUITING

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Baylor Heart Hospital

Plano, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mitch Gheorghiu

Role: primary

310-423-6152

Mane Arabyan

Role: primary

805-796-3746

Caryn Bernstein

Role: primary

404-605-5688

Kristine McGowan

Role: primary

516-881-7035

Marisa Konig

Role: primary

215-662-8456

Saba Ilyas

Role: primary

469-814-4853

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIP-21001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The TRICURE First in Human Trial
NCT05126030 ACTIVE_NOT_RECRUITING NA
The TRICURE EFS Study
NCT06506942 RECRUITING NA